Publication 20080201796 - Transformed plants accumulating mono-and/or sesquiterpenes
|United States Patent Application||Patent Number 20080201796|
|Kind Code||Issued A1|
|Chappell; Joe ; et al.||August 21, 2008|
Transformed plants accumulating mono-and/or sesquiterpenes
The present invention relates to plant expressing transgenes and to plants transformed to comprise additional copies of genes, said genes encoding at least a HMGR-CoA reductase and a terpene synthase. The invention further claims methods for preparing the plants, and a method for producing terpenes. The present thus provides a reliable and cost effective platform for generating any terpene, in particular any mono- and/or sesquiterpene of interest. For example, the skilled person may use any gene encoding a sesquiterpene synthase for accumulating the respective sesquiterpene in the plant of the present invention.
|Inventors:||Joe Chappell (Lexington, KY)
Shuiqin Wu (Lexington, KY)
Michel Schalk (Collonges-Sous-Saleve, FR)
Athony Clark (West Windsor, NJ)
WINSTON & STRAWN LLP;PATENT DEPARTMENT 1700 K STREET, N.W. WASHINGTON DC 20006 US
|Assignee:||University of Kentucky Research FoundationLexington University of Kentucky Research FoundationLexingtonKY|
|Filed:||June 26, 2006|
|PCT Filed:||June 26, 2006|
|371 Date:||November 30, 2007|
|Application Number||Filing Date||Patent Number|
|60696116||Jul 1, 2005|
|Current U.S. Class:||800/260 - 435/3201 - 800/278 - 800/298 - 800/3173|
|Current CPC Class:||C12N 9/0006 20130101; C12N 9/1085 20130101; C12N 15/8243 20130101|
|Class at Publication:||800/260 ; 800/298; 800/317.3; 435/320.1; 800/278|
|International Class:||A01H 1/00 20060101 A01H001/00; A01H 5/00 20060101 A01H005/00; C12N 15/82 20060101 C12N015/82; C12N 15/00 20060101 C12N015/00|
|Jul 7, 2005||EP||05106199.2|
18. A plant expressing a transgene encoding a HMG-CoA reductase (HMGR) and a transgene encoding a terpene synthase (TS).
19. The plant of claim 18, further expressing a transgene encoding a prenyltransferase (PRT).
20. The plant of claim 18, in which products of the transgenes are directed to the cytosol of cells of the plant.
21. The plant of claim 18, in which the TS is a mono- or sesquiterpene synthase.
22. The plant of claim 19, in which the gene encoding a PRT is a geranyl-diphosphate synthase (GPS) or a farnesyl-diphosphate synthase (FPS) encoding gene.
23. The plant of claim 18, in which the transgenes or additional genes are nuclear genes.
24. The plant of claim 18, which accumulates, if compared to a native plant not comprising the transgenes, at least 1.2 times of a terpene that can be synthesised by the TS encoded by the transgene.
25. The plant of claim 18, which accumulates at least 400 ng/g of fresh leaf of a terpene that can be synthesised by the TS encoded by the transgene or by an additional gene.
26. The plant of claim 18, wherein the genes encoding the HMGR, the TS, and if present, prenyltransferase (PRT), are nuclear genes devoid of a plastid targeting sequence.
27. The plant of claim 18, which is Nicotiana Tabacum.
28. A vector comprising a nucleotide sequence encoding at least one prenyltransferase (PRT) or at least one terpene synthase (TS).
29. A method for preparing a transformed plant, which comprises: transforming plant material to comprise additional genes encoding a HMG-CoA reductase (HMGR) and a terpene synthase (TS), and regenerating transformed plants from such plant material.
30. The method of claim 29, wherein the genes encoding the HMGR, the TS, and if present, prenyltransferase (PRT), are nuclear genes devoid of a plastid targeting sequence.
31. A method for preparing a transformed plant, which comprises: transforming a first plant material with a DNA construct comprising at least a gene encoding a terpene synthase (TS); transforming a second plant material with at least one DNA construct comprising at least one gene encoding a HMG-CoA reductase (HMGR); regenerating a first and a second plant from the first and the second transformed plant material, respectively; crossing the first and the second plant; and selecting from progeny obtained by the crossing for plants comprising both, the gene encoding a TS and the gene encoding a HMGR.
32. The method of claim 31, in which the DNA construct comprising a gene encoding a TS, or in which the gene construct comprising a gene encoding a HMGR, further comprises a gene encoding a prenyltransferase (PRT).
33. The method of claim 31, which further comprises crossing the first or the second regenerated plant, or the plants obtained from crossing the first and the second regenerated plant, with a plant transformed to comprise a gene encoding a prenyltransferase (PRT).
34. The method of claim 31, wherein the genes encoding the HMGR, the TS, and if present, prenyltransferase (PRT), are nuclear genes devoid of a plastid targeting sequence.
35. The method of claim 31, wherein the transformation of the plant alters the content of a terpene in the plant.
36. The method of claim 35, wherein the genes encoding the HMGR, the TS, and if present, prenyltransferase (PRT), are nuclear genes devoid of a plastid targeting sequence.
37. A method for producing a terpene, which comprises isolating the terpene from the plant of claim 18.
38. The method of claim 37, wherein the genes encoding the HMGR, the TS, and if present, prenyltransferase (PRT), are nuclear genes devoid of a plastid targeting sequence.
39. A method for producing a terpene, which comprises isolating the terpene from plants obtained from the method of claim 31.
40. The method of claim 39, wherein the genes encoding the HMGR, the TS, and if present, prenyltransferase (PRT), are nuclear genes devoid of a plastid targeting sequence.
 The present invention relates to transformed plants. In particular, transformed plants that accumulate mono- and/or sesquiterpenes. The plants are transformed to over-express or to comprise additional genes encoding a HMG-CoA reductase (HMGR) and a terpene synthase (TS), and, optionally, a prenyltransferase (PRT). The invention further relates to methods for preparing the plants, a method for altering the content of a specific terpene in a plant, a method for producing a terpene and the use of the above-mentioned genes for producing transformed plants.
BACKGROUND OF THE INVENTION AND PROBLEM TO BE SOLVED
 Terpenes and terpenoids are found in most organisms. Their important commercial value, which is constantly increasing, is linked to the diverse range of bioactivities and functionalities encompassed by different terpenes. Accordingly, many vitamins, hormones, insect repellents, drugs, flavors and fragrances are found amongst this very large class of compounds, which all are made starting from units of 5 carbons called isoprene units.
 Terpenes can be classified by the number of isoprene units present in their structure: monoterpenes (C.sub.10), sesquiterpenes (C.sub.15), diterpenes (C.sub.20), triterpenes (C.sub.30), tetraterpenes (C.sub.40) and polyterpenes (C.sub.n, n.gtoreq.45). The plant kingdom contains a high diversity of mono- and sesquiterpenes representing thousands of different structures.
 The chemical synthesis of higher terpenes such as sesquiterpenes is very complex and environmentally acceptable processes for their preparation have not yet been realized. Therefore, it is a first objective of the present invention to provide methods for efficiently producing or accumulating specific terpenes while avoiding multiple-step chemical synthesis.
 Studies on the biosynthetic pathway of terpenes revealed that the common C.sub.5-precursor to all terpenes is isopentenyl diphosphate (IPP). Two distinct pathways for IPP biosynthesis coexist in the plants. The mevalonate pathway (MVA) is found in the cytosol in association with the endoplasmic reticulum and the non-mevalonate pathway, also called deoxyxylulose or methyl-D-erythritol phosphate pathway (DOXP/MEP) is found in the plastids of higher plants. The starting products, the enzymes involved and the catalysed reactions are different in both pathways, and, in the cells of higher plants they operate in parallel and complement each other. Accordingly, the MVA pathway in the cytoplasm is responsible for the biosynthesis of sterols, sesquiterpenes, and polyterpenes, whereas the plastid (MEP pathway) provides C.sub.5-units for the synthesis of monoterpenes, diterpenes, for example kaurene (C.sub.20), and polyterpenes, for example carotenoids (C.sub.40) and plastoquinone-9 (C.sub.45).
 Following the synthesis of IPP, it is repetitively condensed by prenyl transferases (PRT) to form the acyclic prenyl diphosphate terpene precursors for each class of terpenes, that is, geranyl-diphosphate (GPP) for the monoterpenes and farnesyl-diphosphate (FPP) for the sesquiterpenes. These precursors in turn serve as substrate for the terpene synthases or cyclases, which are specific for each class of terpene, e.g. monoterpene, and sesquiterpene synthases. Terpene synthases can catalyze complex multiple step cyclizations to form the large diversity of carbon skeleton of the terpene compounds.
 Attempts have been made to isolate specific terpene synthases and WO2004/031376 reports the isolation of the genes encoding cubebol, valencene and germacrene synthases. When E. coli cells were transformed with plasmids containing these genes, the corresponding fragrance compounds could be found in the cultivating medium. Generally, in view of prior art concerned with heterologous expression of terpene synthases, it is an objective to provide means and methods for accumulating specific terpenes in still higher amounts.
 In U.S. Pat. No. 5,589,619, U.S. Pat. No. 5,365,017, U.S. Pat. No. 5,349,126 and U.S. Pat. No. 5,349,126 processes for increasing squalene and sterol accumulation in transgenic plants are disclosed. These references, however, are silent as to how the accumulation of other classes of terpenes, such as mono- and sesquiterpenes could be increased.
 The preparation of transgenic plants is also the subject of U.S. Pat. No. 6,841,717, which relates to genes associated with the MEP-pathway. This reference teaches a DNA molecule encoding an HMBPP-Synthase (GCPE protein), which was linked to a chloroplast transit peptide and was thus used to produce a transgenic plant. While this reference deals with the accumulation of tocopherol substrates, it is silent how other terpene compounds can effectively be accumulated.
 The present inventors address the problem of producing or accumulating a specific, selected terpene. Preferably, a method is provided, which is suitable to produce not only a pre-determined, but any terpene of interest. The objective is thus to provide a system which allows, for example, the accumulation of any of the above-indicated sesquiterpenes, such as cubebol, valencene, germacrene, patchoulol, but which is also suitable to accumulate other terpenes, in particular monoterpenes. This problem has so far not been solved by the prior art, the latter basically suggesting recombinant organisms having modified properties in the MVA or MEP pathway, and observing that certain terpene end products get accumulated.
 A further objective of the present invention is to provide means for generating any selected terpene, preferably a sesquiterpene, in a stereochemically pure form and with a reliable and cost effective production platform.
SUMMARY OF THE INVENTION
 Remarkably, the present inventors successfully transformed organisms to express a terpene synthase (TS) and an un-regulated form of HMG-CoA reductase (HMGR) and obtained high yields of the terpene that is synthesised by the TS. Surprisingly, in plants transformed with a heterologuous, TS encoding gene alone, terpene accumulation was detectable but was modest and not correlated with TS protein expression levels. An important advantage of the present invention is that any desired terpene can be accumulated in any plant, if the nucleotide sequence encoding the synthase of the selected terpene is known or can routinely be isolated. This is possible by targeting preferably to the cytosol of a plant at least two gene products, that is a HMGR and the enzyme capable of synthesising the terpene, a TS.
 Accordingly, the present invention provides, in a first aspect, a plant expressing a transgene encoding a HMG-CoA reductase (HMGR) and a transgene encoding a terpene synthase (TS).
 In a second aspect, the present invention provides a plant transformed to comprise additional genes, said genes encoding at least a HMGR and a TS.
 In a third aspect, the present invention provides a vector comprising a nucleotide sequence encoding at least one PRT and/or at least one TS.
 In a fourth aspect, the present invention provides a method for preparing a transformed plant, the method comprising the steps of transforming plant material to comprise additional genes, said additional genes encoding a HMGR and a TS, and, regenerating transformed plants from said plant material.
 In a fifth aspect, the present invention provides a further method for preparing a transformed plant, as detailed in the present claims and description.
 In a further aspect, the present invention provides a method for altering the content of a terpene in a plant, the method comprising the steps of the method for transforming a plant.
 In a still further aspect, the present invention provides a method for producing a terpene, the method comprising the step of isolating the terpene from the plant of the invention or obtainable by the methods for preparing a transformed plant.
 In another aspect, the present invention provides the use of at least one gene encoding a HMGR and a TS for producing plants having an altered terpene content.
BRIEF DESCRIPTION OF THE DRAWINGS
 In the figures,
 FIGS. 1A, 1B, 1C and 1D show, in part A and B, a GC-MS analysis of a control tobacco line (part B), and one transformed with both: transgenes encoding a HMG-CoA reductase (HMGR) and a sesquiterpene (patchoulol) synthase (PTS), part A. Peak 10 in chromatogram A is analysed by MS in part C and could be identified as patchoulol by comparison to authentic patchoulol (D). Peak 3 was used as an internal standard (3-.alpha.-cedrene).
 FIG. 2 quantitatively shows the mRNA expression levels in regenerated transgenic plant lines overexpressing a farnesyl diphosphate synthase (FPS), a sesquiterpene (patchoulol) synthase (PTS), or both.
 FIG. 3 shows protein expression levels (western blotting) of the patchoulol synthase (PTS), farnesyl diphosphate synthase (FPS) and fusion protein FPS-PTS proteins in transgenic plants as measured by immunodetection in regenerated transgenic plants.
 FIG. 4 shows patchoulol content in leaves of plants transformed with different constructs. The comparison reveals that high yields of patchoulol (>500 ng/g of fresh leaf FW) were accumulated in plants expressing both, transgenic HMGR and PTS (8PTS). Plants expressing transgenic PTS only (2PTS) typically accumulate less than 500 ng/g patchoulol.
 FIG. 5 shows the organisation of a vector ("pBDON") suitable for A. tumefaciens-mediated transformation of plants, in which the region between the attp2 and the attp1 sequence (cm ccdB) may in vitro and site-specifically be recombined to harbour a HMGR, a TS and, optionally, a PRT. The vector comprises border regions for transformation of plants, promoters, terminators, and the attp1/2 recombination sequences, as discussed in further detail in the examples.
 FIG. 6A and FIG. 6B show helper vectors ("pTMON" and "pTDUAL") comprising, between the attp2 and the attp1 sequence, one or two genes, respectively, to be inserted by site-specific recombination into the vector pBDON of FIG. 5. FIG. 6A shows the helper vector suitable to insert one gene at a time into the pBDON vector, while FIG. 6B shows the helper vector suitable to insert two genes at a time into pBDON. The vectors comprises promotor, terminator, attB1/2 recombination and place-holder sequences "Gene 1" and "Gene 2", as discussed in further detail in the examples.
 FIG. 7 shows the organisation of the T-DNA region of different plant transformation vectors. The HPT region provides hygromycin resistance, PTS encodes a sesquiterpene (patchoulol) synthase, LIS encodes a monoterpene (limonene) synthase, FPS and GPS encode prenyl transferases (respectively a farnesyl diphosphate synthase and a gerany diphosphate synthase). The vector further comprises suitable promoter and terminator sequences.
 FIG. 8 schematically shows the construction of pBDON vector (FIG. 5).
 FIG. 9 schematically shows the construction of pTMON helper vector (FIG. 6 A).
 FIG. 10 part I and FIG. 10 part II schematically show the construction of pTDUAL helper vector (FIG. 6 B).
 FIG. 11 schematically shows the construction of (A) limonene synthase (LIS) and (B) limonene synthase+geranyl diphosphate synthase (GPS) expression vectors for over-expression in transgenic plants.
 FIG. 12 A and FIG. 12 B demonstrate the contribution of over-expressing a truncated form of HMGR in combination with over-expressing of PTS and FPS on patchoulol accumulation in transgenic plants. Part A illustrates the genetic crosses performed between plants first engineered with PTS, PTS+FPS or PTS-FPS gene fusions and plants engineered with a truncated HMGR (AHMGR) gene. Part B shows the results of the evaluation for patchoulol accumulation of the resulting progeny plants. The patchoulol levels (.mu.g/g fr wt) in parental lines (denoted in white) are shown relative to the corresponding progeny lines (reciprocal crosses--black and grey), with the numbers on top of the graphs indicating the average fold improvement in patchoulol accumulation by addition of the HMGR gene. The .DELTA.HMGR parental line (P2) did not accumulate any patchoulol.
 FIG. 13 A shows predicted .sup.13C-labeling patterns in patchoulol bio-synthesised through the MEP or MVA pathway in seedlings grown on [1-.sup.13C]-glucose.
 FIG. 13 B compares MS parent ions for patchoulol synthesized by plants fed .sup.12C-glucose (upper panel), versus synthesis from [1-.sup.13C]-glucose by plants engineered for cytosolic (middle) or plastidic (bottom) biosynthesis.
 FIG. 14 shows limonene production in plants transformed with transgenes encoding a monoterpene (limonene) synthase (LIS) and, in strains 1d and 3a, with a transgene encoding a geranyl diphosphate synthase in addition.
 The sequence listing shows nucleotide sequences used in the preparation of the transformed plants of the present invention. SEQ ID NO: 1 shows the sequence encoding the patchoulol synthase (PTS). Variants of this sequence, for example fused with a nucleotide sequence encoding a His-tag were also used. SEQ ID NO: 2 is a nucleotide sequence encoding an avian farnesyl diphosphate (FPS). SEQ ID NO: 3 shows a nucleotide sequence for the avian FPS fused (bp 1-1134) with a PTS (bp 1144-2802), including a 9 bp linker sequence (bp1135-1143) (FPS-PTS). SEQ ID NO: 4 is a nucleotide sequence encoding a limonene synthase from citrus with the plastid targeting signal removed (LIS). SEQ ID NO: 5 is a nucleotide sequence encoding a geranyl diphosphate synthase from Arabidopsis thaliana with the plastid targeting signal removed (GPS).
 SEQ ID NO: 6-48 are nucleotide sequences of primers used for the present invention.
 SEQ ID NO: 49-57 are peptide sequences used to prepare polyclonal antibodies antibodies for PTS (50-54) and FPS (55-48), respectively.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
 The present invention provides a plant expressing a transgene encoding a HMG-CoA reductase (HMGR) and a transgene encoding a terpene synthase (TS).
 The plant may be any plant, preferably, it is a plant which is suitable to be transformed according to the present invention. Preferably, the plant is a plant, which naturally produces high amounts of terpenes. For example, the plant is selected from the family of Solanaceae, Poaceae or Lamiaceae. For example, the plant is selected from the genera Nicotiana, Solanum, Sorghum, Arabidopsis, Medicago (alfalfa), Gossypium (cotton) Brassica (rape). Preferably, the plant belongs to the species of Nicotiana tabacum.
 The term "expressing", "expression" and the like, for example "expressing a gene" refers to the fact that a gene is transcribed to mRNA and that proteins encoded by the expressed gene are found in the plant. The term "expressing" also encompasses "over-expression", the latter referring to levels of mRNA, protein and/or enzyme activity over and above what is measured in non-transgenic plants.
 The term "transgene" refers to a nucleotide sequence comprising a gene isolated from a foreign organism, generally another kind or species than the plant comprising the transgene.
 The term "gene", as present in the word "transgene", for example, refers to a nucleotide sequence that can be translated by the plant of the invention to a protein having the activity indicated, for example a terpene synthase. For the purpose of the present invention, the term "gene" may also include non-coding regions, as long as the final protein construct expressed in the plant shows the activity mentioned.
 Accordingly, a gene encoding an enzyme, such as a HMGR, for example, including transgenes, refers to a nucleotide sequence comprising information for the preparation of at least one polypeptide.
 The present invention further provides a plant transformed to comprise additional genes, said genes encoding at least a HMGR and a TS.
 The term "transformed", such as a transformed plant, refers to the fact that a plant has been subjected to genetic engineering. A "transformed plant", includes asexually (vegetative) and sexually derived progeny of an individual plant that has been transformed. For example, plants obtained by crossing of a plant having individually been transformed with untransformed plants is encompassed by the present invention, if the progeny contains the additional genes and/or transgenes as required by the present invention.
 Within the context of this specification the word "comprises" is taken to mean "includes, among other things". It is not intended to be construed as "consists only of".
 The term a plant transformed to comprise "additional genes" refers to plants that, due to genetic engineering, comprise new or foreign DNA (for example, genes) inserted into any position of the entire genome of a plant (nuclear, mitochondrial and plastid) that were not present at this position before the genetic engineering.
 The plants of the present invention comprise genes encoding an HMG-CoA reductase (HMGR). A HMGR is an enzyme that is capable of catalizing the reductive deacylation of 3-hydroxy-3-methylglutaryl-Coenzyme A to mevalonate. The term HMGR encompasses all classes of HMGR, in particular classes I and II. The term HMRG encompasses enzymes having EC number EC 22.214.171.124. HMGRs are present in all eucaryotic organisms and also in many bacteria.
 The present invention is not limited to a specific nucleotide sequences encoding a specific HMGR, much to the contrary, any HMGR may be selected for the purpose of the present invention. The skilled person may thus select any gene isolated from any organism encoding a HMGR from the literature or from public databases. In addition, the skilled person may routinely isolate new genes encoding HMGRs, for example, from any organism. Given that over 60 nucleotide sequences encoding HMGRs from various organisms have already been isolated and are readily available to the skilled person, a list of specific HMGRs need not be provided here.
 Preferably, the HMGR gene is heterologuous to the plant of the present invention. More preferably, it is a non-plant HMGR, for example a HMGR gene isolated from an animal is used.
 Preferably, the gene encodes a soluble and not membrane-bound HMGR. This may be achieved by truncating the membrane-binding region encoded by a nucleotide sequence and using a nucleotide sequence encoding a HMGR devoid of a membrane binding region. Alternatively, genes encoding an HMGR lacking a membrane domain have been isolated from Leishmania major and may also be used for the purpose of the present invention.
 Preferably, the gene encoding a HMGR is under the direction of a strong, unregulated constitutive promoter.
 Tobacco plants comprising additional genes encoding a HMGR and/or over-expressing HMGR are disclosed in U.S. Pat. No. 5,306,862, U.S. Pat. No. 5,349,126, U.S. Pat. No. 5,365,017, U.S. Pat. No. 5,589,619, for example, all of which are expressly incorporated herein by reference. These plants may be used for the purpose of the present invention, and may be transformed to comprise at least a transgene and/or a copy of an additional gene encoding a TS.
 The plants of the present invention comprise at least one gene encoding a TS. TSs are enzymes that catalyse the formation of a terpene from a given precursor compound. According to a preferred embodiment, the TS is a mono- and/or a sesquiterpene synthase. A monterpene synthase is an enzyme that catalyses the formation of a monoterpene (C.sub.10-compound) with geranyl diphosphate as precursor. A sesquiterpene synthase is an enzyme capable of catalizing the formation of a sesquiterpene (C.sub.15) from farnesyl-diphosphate.
 Therefore, in contrast to HMGRs, which always produce mevalonate, the TS of the present invention may be selected from different enzymes having different reaction products. Accordingly, the term TS refers to many different TSs capable of synthesising, altogether, thousands of different terpene compounds.
 An important advantage of the present invention is thus the large choice of selecting any desired TS. Depending on the terpene that the skilled person wants to produce or have accumulated in the plant of the present invention, the nucleotide sequence that is capable of synthesising the respective terpene may freely be selected. In this way, the present invention provides a cost-efficient platform for the production of any terpene of interest.
 For illustrating the principle of the present invention, a few TS for which the genetic information is available are provided as examples: Examples of monoterpene synthases are the limonene synthase (LS) (Ohara et al, 2003) and S-linalool synthase (LIS). (Lucker et al 2001).
 According to a preferred embodiment, the TS is a sesquiterpene synthase. Given that thousands of sesquiterpenes have been described so far, a corresponding number of sesquiterpene synthases may serve as a pool from which the gene encoding a sesquiterpene synthase may be selected from. Accordingly, the gene encoding a sesquiterpene synthase may be selected from publicly accessible databases, from the literature, or from so far undiscovered genes that the skilled person can readily isolate from organisms by routine experiments and well-known isolation procedures. For example, the TS may be capable of synthesizing .beta.-caryophyllene, .alpha.-humulene, germacrene A, B, C, D, valencene, aristolochene, vetispiradiene, patchoulol, cubebol, .gamma.-curcumene, (-)-germacrene D, (+)-germacrene D, bicyclo-germacrene, and/or .delta.-cadiene synthase. The genes of some of the TSs capable of synthesising the above sesquiterpenes are disclosed in the international applications PCT/IB/2004/003836 and WO 2004/031376.
 For example, the terpene that can be synthesized by the TS is a fragrance, flavor, medicament, insecticide, fungicide, and/or herbicide. Preferably, it is a fragrance.
 A "terpene" is a hydrocarbon based on or composed of isoprene units (C.sub.5H.sub.8), which may be cyclic or acyclic. For the purpose of the present invention the terms "terpene", "mono-", "di" and/or "sesquiterpene" also include terpene derivatives, such as terpenoids, which include hydrocarbons that have undergone one or more steps of functionalization such as hydroxylations, isomerizations, oxido-reductions, dimethylation, or acylation, for example.
 The genes encoding a HMGR and a TS may, for example, be present in the form of one single gene encoding a fusion protein having both, TS and HMGR activity.
 According to a preferred embodiment, the plant of the present invention further expresses a transgene encoding a prenyl transferase (PRT), or is transformed to comprise additional genes encoding a PRT.
 Prenyl transferases (PRT), also called polyprenyl diphosphate synthases or polyprenyl pyrophosphate synthases are enzymes that catalyse alkylation steps involving dimethylallyl diphosphate (DMAPP) and one or more IPP residues, for example farnesyl diphosphate (FPP), geranyl diphosphate (GPP), or others. The term PRT also includes one or several distinct enzymes capable of catalysing one or a sequence of reactions leading to the polyprenyl diphosphate precursor for the various terpenoid families. Therefore, the at least one nucleotide sequence encoding a PRT, for the purpose of the present invention, encompasses sequences encoding for polypeptides having quaternary structures comprising homo- and hetero mixtures of mono-, di-, tri-, tetra-, and ologomeric proteins. In particular, the PRT may be a monomer, a hetero- and/or a homo-dimer. The geranyl diphosphate synthase from oil glands of peppermint (Mentha piperita) may serve as an example for the complex genetic organisation of certain PRTs encompassed by the present invention, as this enzyme has been purified and was revealed to be a heterodimer, with both subunits required to produce GPP from IPP and DMAPP precursors.
 Preferably, PRTs encompass enzymes classified under EC number EC 2.5.1, for example.
 In a preferred embodiment, the at least one gene encoding a PRT is a geranyl-diphosphate (GPP) synthase and/or farnesyl-diphosphate (FPP). GPP and FPP are the precursors for mono- and sesquiterpenes, respectively.
 Geranyl-diphosphate synthases (GPS), also called dimethyl-allyl-transtransferases, are examples for PRTs.
 According to a preferred embodiment, the PRT is a farnesyl diphosphate synthase (FPS). FPSs are enzymes that catalyse, for example, the condensations of geranyl diphosphate (GPP) with IPP to give farnesyl diphosphate. Preferably, the FPS is capable of catalysing the sequential condensation of isopentenyl diphosphate (IPP) with the allylic diphosphates, dimethylallyl diphosphate (DMAPP), and then with the resultant geranyl diphosphate (GPP) to the ultimate product farnesyl diphosphate.
 Preferably, the gene PRT is selected to provide the precursor for the selected TS in the plant of the present invention. For example, if the plant comprises an additional gene encoding a sesquiterpene synthase it further comprises an additional gene encoding a farnesyl-diphosphate synthase.
 Similar to the genes encoding HMGRs and TSs, genes encoding PRTs are publicly available and may be selected by the skilled person from various origins. Publicly available databases suitable for obtaining nucleotide sequences encoding HMGRs, PRTs and/or TS are, for example, the database of the European Bioinformatics Institute, (http://www.ebi.ac.uk/swissprot/index.html), the EXPASY database (http://www.expasy.org/enzyme/), the NCBI database (http://www.ncbi.nlm.nihgov) and many others. For the mere purpose of illustrating the many possibilities of FPSs available to the skilled person that could be used for the purpose of the present invention, one could cite a geranyl diphosphate synthase isolated from Ips pini (NCBI Accession number (AN): AY 953508.1), a farnesyl diphosphate synthase isolated from Vibrio fischeri (NCBI AN: YP 203660), and an avian farnesyl diphosphate synthase reported by Tarshis et al (1994). Of course, any other PRT could be selected from any database or origin.
 According to a preferred embodiment, the products of the additional and/or genes are directed to the cytosol of cells of the plant. Gene product may be directed to the cytosol of the plant by various means. For example, plants may be transformed to comprise copies of the genes in the nuclear chromosome, said genes being free from any plastid targeting sequence, and/or any other organelle targeting information. This is relevant, for example, for many of the known monoterpene synthases, which often comprise plastid-targeting sequences, their principle site of activity being the plastid. In this case, the plastid targeting sequence should be removed from the additional gene and/or transgene encoding a TS and/or a PRT, before transforming a plant with it. Accordingly, in a preferred embodiment, the genes and/or transgenes are expressed in nuclei of the plant. Preferably, they are part of a plant chromosome.
 Preferably, the gene products (TS, HMGR, optionally PTR) encoded by the additional genes and/or transgenes present in the plants of the invention are active. Preferably, they are active in vivo and/or in vitro. Standard assays may be used to determine activity of enzymes in transformed plants. An essay for quantitatively assessing HMGR activity in transformed plants is disclosed in U.S. Pat. No. 5,349,126, Example 2, referring to the method of Chappell et al, Plant Physiol., 85:469-473 (1987). In WO 04/031376, Example 4, an enzyme function assay for a sesquiterpene synthase is disclosed. Both assays disclosed in the above references are incorporated herein by reference. Assays for assessing PRT activity may be found in the literature, too.
 In a preferred embodiment, the plant of the present invention accumulates, if compared to a native, untransformed plant, at least 1.2 times of a terpene that can be synthesised by the TS encoded by the transgened and/or additional gene. Preferably, the transformed plant accumulates at least 1.5 times, twice, three times, more preferably at least four times and most preferably at least 6 times as much of the specific terpene.
 According to another embodiment of the invention, the transformed plant accumulates at least 400 ng/per g of fresh leaf of a terpene that can be synthesized by the TS encoded by the transgene and/or additional gene. Preferably, the transformed plant accumulates at least 500 ng, more preferably at least 800 ng, even more preferably at least 1000 ng, still more preferably at least 2000 ng, even more preferably at least 5000 ng, still more preferably 7000 ng and yet more preferably at least 8 .mu.g of the specific terpene that can be synthesized by the recombinant TS present in the transformed plant. Most preferably, the transformed plant accumulates at least 10000 ng or even more of the specific terpene per g of fresh leaf. For example, the transformed plant accumulates 2-16, preferably 4-12 .mu.g of terpene per g of fresh leaf. The quantity of the specific terpene may also be expressed in weight of dry matter. In this case, dry matter plant materials, and in particular leaves, corresponds to about 10% of the values for fresh weight. Accordingly, at least 4, 5, 8, 10, 20, 50, 70 or 100 .mu.g terpene per g of dry leaf are accumulated.
 In case the native, untransformed plant already produces the specific terpene that can be synthesised by the TS, the values valid for the transformed plant are added to the amount of the specific terpene natively present in the untransformed plant.
 For determination of the content of the specific terpene in the plant of the present invention, any plant organ producing or accumulating terpenes may be taken as a reference. Preferably, green leaves having the same age (preferably adult leaves) are taken from the transformed and non-transformed plant, respectively, for comparison. The analysis is preferably conducted according to the protocol "Terpene analysis" outlined in the examples. Preferably, fresh leaves are analysed directly after cutting from the plant. Leaves may be frozen after harvesting and be analysed in the frozen state.
 According to a preferred embodiment, the transformed plant according to the invention is the transformed Nicotiana tabacum cv Xanthi deposited at the ATCC under the sample designation "8hsPTS-10" and the ATCC number ATCC PTA-6706.
 Preferably, the transformed plants may comprise knock-out, down-regulating, deletion or other forms of deleterious mutations in selected wild-type genes participating to the terpene biosynthetic pathways suitable to deviate the carbon flux away from conventional terpenes to that of the TS of the present invention. Preferably, these conventional, other terpene pathways are down-regulated. For example, the plants of the present invention may have one or more non-, or reduced functional genes downstream the FPP, GPP and/or GGPP synthases encoding genes leading to the synthesis of sterols, polyprenoids, phytols and carotenoids. In this way, carbon-flux may more efficiently be directed towards the synthesis of the specific terpene.
 The present invention provides a vector comprising a nucleotide sequence encoding at least one PRT and/or at least one TS. Preferably, the vector further comprises a nucleotide sequence comprising a HMGR-encoding gene. Preferably, the vector comprising a nucleotide sequence encoding one, two or all selected from the group consisting of HMGR, TS and/or PRT is free of a plastid targeting sequence linked to the HMGR, TS, and/or PRT.
 Preferably, the vector further comprises promoter and terminator sequences, preferably up-stream and downstream the nucleotide sequence including the plastid targeting sequence and the gene for the HMGR, TS and/or PRT, respectively. Preferably, the vector comprises strong constitutive promoters. Commercially available examples for promoters are the FMV, figwort mosaic virus, ACT2, actin, MAS, mannopine synthase and the NOS promoter. Preferably, the promoters are selected to be independent from control and/or feed back regulation mechanisms of the untransformed host plant. Preferably, the recombinant HMGR and TS have up-stream promoter sequences. More preferably, they have each different promoter sequences.
 Optionally, the vector may further comprise tags suitable for antibody binding, such as His-tags and/or myc tags.
 Preferably, the vector of the present invention further comprises a marker suitable for selecting transformed plants. For example, the vector may comprise genes conferring a hygromycin or a kanamycin resistance, or any other kind of marker suitable to select for successfully transformed plants.
 Preferably, the vector of the present invention further comprises left and right T-DNA border regions, flanking the HMGR, TS, and, optionally PRT, including optional promoter, terminator, and/or tagging sequences, as well as plant resistance markers, in order to facilitate transfer and integration of the structural genes into the plant nuclear genome.
 Accordingly, the vector of the present invention preferably comprises structural genes encoding a HMGR, PRT and/or a TS, and a marker for selection of transformed plants, flanked by left and right border regions facilitating insertion into the plant genome.
 Preferably, the vector further comprises, outside the left and right border region, a marker for selecting positive bacterial transformants used to clone bacteria comprising the vector or used for transformation of plants (A. tumefaciens).
 In a preferred embodiment, the vector of the present invention is the plasmid deposited at the ATCC with the sample reference "pBhsPTS" and the ATCC number PTA-6707.
 In an aspect, the present invention relates to a method for preparing a transformed plant, the method comprising the steps of transforming plant material to comprise additional genes, said additional genes encoding a HMGR and a TS, and, regenerating transformed plants from said plant material.
 For the step of transforming plant material, any method for transforming plants with the genes of the present invention may be employed. For example, plant cells that have been stripped of their protective cell walls take up pure DNA when treated with certain membrane-active agents or with electroporation. DNA can also be microinjected into target plant cells using very thin glass needles. A recently developed method of plant transformation, biolistics, involves accelerating very small particles of tungsten or gold coated with DNA into cells using an electrostatic pulse, air pressure, or gunpowder percussion.
 The present inventors have obtained good results with the Agrobacterium tumefaciens-mediated transformation. Preferably, plasmid constructs (vectors) comprising at least one of the structural genes of the present invention, flanked by nucleotide sequences that allow integration of the structural genes into the plant nuclear chromosome DNA are used, such as those disclosed above.
 Accordingly, in an embodiment of the plants, the methods or uses of the present invention, the genes encoding HMGR, the TS, and if present, the PRT, are nuclear genes, preferably devoid of a plastid targeting sequence. These genes are preferably present in the nuclear chromosome of the plant of the present invention.
 Transformation of plant material with DNA constructs, for example comprising genes encoding a HMGR, TS, and/or PRT may be performed by standard methods, see Schardl et al, Gene (1987) .delta.: 61:1-11; Berger et al, Proc Natl Acad Sci USA (1989) 86:8402-8406; and Horsch et al, Science (1985) 27:1229-1231, the latter method describing the "leaf disk method", which is particularly suitable for transforming Nicotiana tabacum.
 The methods of the present invention further comprise the step of regenerating the transformed plant from the transformed plant material. Methods for regenerating entire plants from transformed plant material are routinely applied by the skilled person. For example, the method disclosed by Horsch et al (1985) may be employed. In general, segments of leaves inoculated by insert DNA containing A. tumefaciens may be grown in selective media until callus and regenerated plant shoots are evident. Shoots of 1-3 cm in size may be transferred to T-Media (Schardl, 1987) containing antibiotics to stimulate root development. Once root systems are established, the plantlets may be transferred to commercially available potting soil and propagated in a greenhouse. Accordingly, in a preferred embodiment, the method for preparing a transformed plant further comprises the step of cultivating the transformed plant.
 In an aspect, the present invention provides a further method for preparing a transformed plant, the method comprising the steps of transforming a first plant material with a DNA construct comprising at least a gene encoding a TS, transforming a second plant material with at least one DNA construct comprising at least one gene encoding a HMGR, regenerating a first and a second plant from the first and the second transformed plant material, respectively, crossing the first and the second plant, and, selecting from progeny obtained by the crossing for plants comprising both, the gene encoding a TS and the gene encoding a HMGR.
 In a preferred embodiment, the DNA construct comprising a gene encoding a TS, or in which the gene construct comprising a gene encoding a HMGR, further comprises a PRT.
 The above method is an alternative method for obtaining the transformed plant of the invention, in that different plant material is separately transformed with a structural gene encoding a HMGR or a TS, and transformed plants are regenerated comprising only one of the at least two recombinant genes.
 In a following step, sexually derived progeny are obtained from crossing plants containing recombinant, heterologuous and/or transgenic HMGR DNA with plants comprising recombinant, heterologuous and/or transgenic TS DNA. Preferably, crossing refers to genetic, also called Mendelian crossing. This can typically be done by cross-pollinating. Among the progeny, individuals expressing both, the recombinant PRT as well as the TS are selected. For example, plants already over-expressing HMGR, such as those disclosed in U.S. Pat. No. 5,306,862, U.S. Pat. No. 5,349,126, U.S. Pat. No. 5,365,017 and U.S. Pat. No. 5,589,619 may be crossed with plants transformed to comprise transgenes encoding a TS, for example. In the same way (Mendelian crossing) a transgene encoding a PRT may be introduced.
 Accordingly, in an embodiment, the method further provides the step of crossing the first and/or the second regenerated plant, or the plants obtained from crossing the first and the second regenerated plant, with a plant transformed to comprise a gene encoding a PRT.
 Alternatively, an additional transgene encoding a PRT may be introduced by transforming a plant already over-expressing HMGR and/or comprising additional genes and/or expressing a transgene encoding a TS with a DNA construct comprising a gene encoding a PRT.
 The methods of the present invention for preparing transformed plants have the purpose of obtaining accumulation of a desired terpene in the transformed plant. The transformed plant are thus preferably screened for transformants accumulating high amounts of the terpene in the plant. The steps of the methods of preparing transformed plants are thus equally suitable as methods for altering the content of a terpene in a plant, which latter methods represent further preferred embodiments of the present invention. Similarly, the above disclosed methods and plants also illustrate an aspect of the present invention, which is the use of genes encoding HMGR and/or TS, and, optionally at least one further gene encoding a PRT for producing plants having an altered terpene content, and preferably an increased content of a specific terpene.
 The present invention further relates to a method for producing a terpene, the method comprising the step of isolating the terpene from the plant of the invention or from the plant obtainable by the methods of preparing transformed plants. The transformed plant may be cultivated and harvested, preferably in sufficiently high yield and/or on a sufficiently large scale to render the process economically favourable. The specific terpenes of the invention may be isolated by any method used in the art including organic solvent extraction or distillation and may be quantified and/or identified by gas chromatography (GC)-mass spectrometry (MS).
 The following examples are intended to illustrate the invention without limiting the scope as a result. Methods and protocols of the examples are generally performed following standard protocols supplied by the manufacturer of specific materials or kits, or by following well-established protocols defined by Sambrook et al (1989) and Ausubel et al. (1987).
 All primers used are listed in the attached sequence listing. For some method or protocol steps, reference is made to the literature, which is listed further below in more detail, and which is expressly incorporated herein by reference.
Selection of Plant Material
 The homozygous line of Nicotiana tobacum `Xanthi` line containing a truncated hamster hydroxymethyl-glutaryl-CoA reductase gene, referred to hereafter as 14-8, and a F2 segregating sibling line lacking the transgene, hereafter referred to as 14-2, were developed as described by Chappell et al. (1995) and in patents U.S. Pat. No. 5,306,862, U.S. Pat. No. 5,349,126, U.S. Pat. No. 5,365,017. In brief, the hamster gene first characterized by Chin et al. (1984) was modified by removing nucleotides 28 to 1023 to generate a truncated form of the gene referred to as delta-227 HMGR. A BamH1/Sst1 fragment of the truncated HMGR cDNA was isolated and inserted into an intermediate plasmid vector, pKYLX 61, and an EcoR1/Cla1 fragment of that construct was subsequently inserted into the corresponding site of pKYLX71 to generate the pKYLX71-truncated HMGR gene construct. The Ti-plasmid series pKYLX61 and 71 were developed by Schardl et al. (1987).
 The pKYLX71-HMGR plasmid was mobilized into Agrobacterium tumefaciens harboring the disarmed Ti plasmid GV3850 using standard triparental mating procedures (Schardl et al., 1987). Leaf discs of Nicotiana tabacum L. cv. Xanthi were used as plant material and were inoculated with the Agrobacterium carrying the pKYLX71-HMGR construct and transgenic plants were regenerated using the standard transformation and regeneration protocols described in Schardl et al. (1987) and Horsch et al. (1985).
 Primary transformed and regenerated plants (R0 generation) were grown and allowed to self-pollinate and the subsequent seed collected (R1 generation). R1 seeds were grown as individual plants under standard greenhouse conditions, allowed to self-pollinate and the R2 seed generation collected. The R2 seed generation was subsequently screened for the presence of the HMGR transgene.
 Screens for the presence of the HMGR transgene constructs were initially based on the presence of the kanamycin resistance marker which was engineered into the plants as part of the pKYLX71-HMGR construct (Chappell et al., 1995). Seeds plated onto germination media containing 100 mg of kanamycin/L were scored for germinated seedlings exhibiting photobleaching (all white seedlings, those lacking the kanamycin resistance marker, and thus homozygous lines lacking the transgene constructs) versus all green seedlings (green seedlings harboring the kanamycin resistance marker, and thus homozygous lines containing the transgene constructs). Seed from these identified lines were subsequently propagated in the greenhouse (without kanamycin selection) and screened for the presence of the engineered HMGR construct by chemical analysis for sterols (Chappell et al., 1995). Line 14-8 exhibited sterol levels 2-10 fold higher than control plants and all seedlings grew normally in the presence of kanamycin, while line 14-2 contained sterol levels comparable to non-transformed, control plants and seedlings germinated in the presence of kanamycin were all photobleached white.
 Plant lines 14-8 (HMGR-over-expressing) and 14-2 (control) were used in all subsequent transformation work.
Construction of Recombination and Plant Transformation Vectors
 The hygromycin selection marker (Hajdukiewicz et al., 1994) was chosen for creating a selection marker for transformed plants. New vectors were engineered with appropriate recombination cloning sites as described by Hartley et al. (2000).
Development of the PBDON Vector
 The pBI101 vector (Invitrogen, Carlsbad, Calif.) was digested with the restriction enzymes Sph1 and Sst1 and the DNA fragment corresponding to the plasmid vector (not including the RB border and NPTII gene cassette) was isolated by agarose gel purification (Sambrook et al, 1989), (1) in FIG. 8. In parallel, an attp recombination cassette including the ccdb gene and chloroamphenical resistance gene was amplified from the pDON221 vector (Invitrogen, Carlsbad, Calif.) using standard PCR conditions with primers Attp1-SstI-FW and Attp2-SphI-RV (2). The PCR amplified DNA fragment was restricted with the Sph1/Sst1 enzymes, gel purified and ligated into the corresponding sites of the similarly digested pBI101 vector described above to yield the intermediate pBattp vector (3).
 A hygromycin gene cassette was prepared in a 2-step process. First, the hygromycin gene (HPT) and CaUTR (termination sequence) was PCR amplified from the pCAMBIA1301 (Cambia, Can berra, AU) vector using the PCR primers HPT-NotI-FD and HPT-Xba1-RV, and T/A cloned (Taq-Amplified PCR products directly from the PCR reaction mix) into the pT7Blue vector (Novagen, Madison, Wis.) to yield pTHPT (4). The right border (RB) and the NOS-promoter (P-NOS) regions were amplified from pBI101 using the PCR primers TB-SphI-FD and TB-NotI-RV (5), then T/A cloned into the pT7Blue vector giving rise to vector pTRBP (6). The hygromycin resistance gene cassette was released from vector pTHPT via digestion with Not1/Xba1 (7), and cloned into the similarly digested pTRBP vector, resulting in vector pTRBPHPTT (8). The NOS promoter-hygromycin-CaUTR cassette was then amplified from this vector using the primers TB-SphI-FD and HPT-SphI-R (9). The amplified product was digested with Sph1 and ligated into the corresponding site of pBattp, yielding the pBDON vector (10).
 The pBDON Ti-vector (FIGS. 5, 9) contains an NPTII selection marker outside the T-DNA region for selection in bacteria and the hygromycin gene (HPT) for plant transformation selection. The embedded attp cassette hence provides for the easy insertion of target gene constructs flanked with attB sites into the pBDON vector.
 Development of helper vectors with attB sites:
 Two different attB help vectors were constructed following the protocol given in FIGS. 9 and 10. One for single gene insertion (PTMON, FIG. 6 A) and the other for two target gene insertions into the pBDON vector (pTDUAL, FIG. 6 B).
Generation of the PTMON Vector
 The pTMON vector was constructed by first amplifying the cassaya mosaic virus (Pcv) promoter from a modified pBI101 vector with a forward PCR primer containing a Nde1 restriction site and an attB1 sequence embedded into the primer CSMV-ATTB1-SGFI-FD, and the reverse primer CSMV-ECORI-RV containing an EcoR1 site (11). The PCR fragment was T/A cloned into the pGem-Teasy vector (Promega, Madison, Wis.) (12), then re-isolated as a Nde1/EcoR1 digestion product. The isolated digestion product (13) was ligated into the corresponding restriction sites of the pECVS vector, a pET28a derivative harboring an optional placeholder gene, "Gene 1", NCBI accession number CQ813508) to generate pEPCVS (14).
 In parallel, the NOS terminator (TNOS) sequence of pBI101 was amplified with the forward primer Tnos-XhoI-FW and the reverse primer Tnos-attB2-RV, which incorporated an attB2 recombination site downstream of the TNOS sequence. The PCR fragment was T/A cloned into the pGEM-Teasy vector, yielding the pTTNOS vector (15). An Nde1/Xho1 digestion fragment of pEPCVS (16) was subsequently ligated into the corresponding sites of pTTNOS to generate pTMON (17) (FIGS. 6A, 9).
 The pTMON vector was constructed for insertion of a single target gene behind a cassaya mosiac virus promoter (Pcv) (Frey et al. 2001) and followed by the Nos terminator sequence.
 In some cases, a His-Tag sequence was engineered into the pTMON vector by digestion with EcoR1, followed by linker/ligation with the primer pair His-EcoF and His-EcoR. Subsequent mutation was designed to abolish the His-Tag open-reading frame sequence, but to maintain convenient Asc1 and EcoR1 restriction sites. This was accomplished using standard PCR reaction conditions with primers mH is PTS-F and mH is PTS-R, and transforming the PCR reaction products into bacteria to recover the mutated pTMON plasmid.
Generation of the pTDUAL Vector
FIGS. 10 I and II
 The pTDUAL vector was constructed in a multi-step process (FIG. 10, part 1 and 2). First, the cauliflower mosaic virus promoter (Pca) (Benfy et al. 1990) was amplified from the pBI121 vector (Invitrogen) using the primers PCaMV-XbaI-FW and PCaMV-SpeI-RV, and T/A cloned into the pT7Blue vector (18). The promoter element was subsequently released from this vector by digestion with Xba1 and Spe1 (19). In parallel, an optional placeholder gene ("Gene 2"), was amplified from a Hyoscyamus muticus cDNA library obtained from an elicitor treated cell culture (PCT/US06/02265) with the primers 7120D-SpeI-FW and 7120D-KpnI-RV, followed by digestion with Spe1/Kpn1 and ligation into the corresponding site of a pT7Blue vector and yielding pTHPO (20). pTHPO was then digested with Xba1/Spe1 and the CaMV promoter fragment similarly released from pTPCa were ligated together to give pTPHPO (21).
 In parallel to build pTPHPO, the NOS terminator sequence was amplified from the pGTNOS vector with primers Tnos-KpnI-FW and Tnos-attB2-RV3, T/A cloned into the pGem-Teasy vector (22) followed by subsequent re-isolation of the fragment by digestion of the pGTNOSK plasmid with Kpn1 and Sac1 (23). This fragment was then cloned into the corresponding restriction sites of pTPHPO to yield pTPHPOT (part 1 of FIG. 10) (24).
 In the final steps of constructing the pTDUAL vector, a fragment (25) of the pTMON vector spanning from the attB1 site to the nos-terminator sequence downstream of the inserted terpene synthase gene was amplified using standard PCR conditions. The amplification product was obtained with primers CsMV-attB1-Sgf I-FD and TNOS-XbaI-RV, which also engineered terminal Sph1 and Xba1 sites onto the fragment. The PCR fragment was digested and ligated into the corresponding Sph1/Xba1 sites of the pT7Blue vector, generating pTPCVST (26). Finally, an Xba1 to Sac1 digestion fragment (27) from pTPHPOT was ligated into the corresponding sites of pTPCVST to create the pTDUAL vector (25), which allows for the insertion of 2 gene sequences downstream of strong, constitutive expression promoters (FIG. 10 part 2).
 The pTDUAL vector (FIG. 6 B) was designed for the insertion of two genes into transgenic plants. Expression of the first gene is directed by the cassava mosaic virus promoter (Frey et al. 2001), while expression of the second gene is directed by a cauliflower mosaic virus promoter (Benfey et al. 1990).
 Similar to the modifications made to the pTMON construct described above, in some cases a His-Tag sequence was engineered into the pTDUAL vector by digestion with EcoR1, followed by linker/ligation with the primer pair His-EcoF and His-EcoR. Subsequent mutation was also designed to abolish the His-Tag open-reading frame sequence, but to maintain convenient Asc1 and EcoR1 restriction sites. This was accomplished using standard PCR reaction conditions with primers mH is PTS-F and mH is PTS-R, and transforming the PCR reaction products into bacteria to recover the mutated pTDUAL plasmid.
Construction of the Patchoulol Synthase (PTS) and Patchoulol Synthase+Farnesyl Diphosphate Synthase (FPP) Over-Expression Vectors
 Generation of the PTS and PTS+FPS expression vectors were greatly facilitated by the appropriate recombination cloning sites associated with the pTMON, pTDUAL and pBDON vectors. The PTS (WO 2004/031376) or FPS genes (Tarshis et al, 1994) were amplified with primer pairs PTS-AscF and PTS-XhoR, or FPP-SpeFW and FPP-KpnRV, respectively, digested with either Asc1/Xho1 or Spe1/Kpn1, then ligated into the corresponding sites of the pTMON or pTDUAL vectors. The FPS-PTS gene fusion was created by amplifying the FPS gene with primers FPS-AscF and FPS-AscR, digesting the resulting PCR fragment with Asc1 and ligating this fragment into the corresponding Asc1 site found 5' to the PTS gene in the pTMON and pTDUAL vectors. The resulting plasmids were then used to mobilize the corresponding PTS, PTS+FPS and FPS-PTS gene cassettes into the pBDON vector by standard recombination cloning (Hartley et al. 2000) generating a family of Ti-plasmid vectors (FIG. 7). A plasmid pBDON vector comprising a PTS encoding gene with a His-tag corresponding to the first cassette shown in FIG. 7 was deposited under deposit number ATCC PTA-6707.
Plant Transformation and Regeneration
 Individual pBDON vector constructs (FIGS. 5, 7) were transformed into Agrobacterium tumefaciens strain GV3850 by electroporation (Mersereau et al. 1990) and transformants selected for kanamycin resistance. Selected colonies were verified for the transgene constructs by limited DNA sequencing and subsequently grown in 50 mL of LB media containing 100 mg kanamycin/L. Overnight cultures having an OD600 equal to 0.6-0.8 were concentrated by centrifugation, resuspended in a 30 mL of fresh LB medium (without antibiotic) and used for inoculation of leaf explants as described previous (Chappell et al., 1995; Horsch et al, 1985). In brief, leaves from plants grown under sterile conditions were placed into the Agrobacterium cultures, cut into approximate 1 cm segments, and the leaf segments plated on non-selective media plates (Murashige and Skoog, 1962). After 3 days, the leaf explants were transferred to media plates containing 15 .mu.g/mL hygromycin (Invitrogen, Carlsbad, Calif.) and 500 .mu.g/mL cefotaxime (Bioworld, Dublin, Ohio) and subsequently to the same selection media weekly until callus and re-generated plant shoots were evident. Shoots of 1-3 cm in size were then transferred to T-media (Murashige and Skoog, 1962) (containing the same antibiotics) to stimulate root development. Once root systems were established, the plantlets were transferred to commercially available potting soil and propagated in a greenhouse.
 Sesquiterpenes extracted from leaf material of transformed plants obtained in Example 6 were identified and quantified by GC-MS analysis. Frozen leaf samples of 200-500 mg were ground in liquid nitrogen, then extracted with 3 mL of a hexane:ethyl acetate mixture (v/v 85:15) containing 200 ng of .alpha.-cedrene as an external standard. The extract was partially purified by running the sample over a silica column eluted with the same 85:15 mixture of ethyl acetate:hexane. The eluate was concentrated under a stream of nitrogen to 30 .mu.L before analyzing 1 .mu.L aliquots by GC-MS (Takahashi S, 2005). Samples were injected onto a Trace GC-MS (ThermoFinnigan, Somerset, N.J.) equipped with a Restec Rtx-5 capillary column (30 m.times.0.32 mm, 0.25 .mu.m phase thickness) operated in the splitless mode with an injector temperature of 250.degree. C. and an initial oven temperature of 70.degree. C. for 1 min, followed by a 4.degree. C. per min gradient to 230.degree. C. Mass spectra were recorded at 70 eV, scanning from 35 to 300 atomic mass units, and compared to library standards (NIST library) and authentic standards for verification.
 The estimation of the quantities of patchoulol was based on the ratio of peak areas obtained by total ion monitoring for patchoulol and the internal standard. The response factor of .alpha.-cedrene and patchoulol was calculated by co-injection of the same quantities of the corresponding standards and the resulting correction factor was included in the calculation. The same method was used for the quantification of limonene and other terpene molecules.
 FIG. 1 shows the results of terpene analysis of a control tobacco line (WT) and one transformed with HMGR and PTS gene constructs for sesquiterpene content. In FIG. 1, a total ion chromatogram for a HMGR over-expressing line transformed with the HisPTS gene constructs (FIG. 1 A) is compared to that for a control plant (transformed with the HMGR only) (FIG. 1 B). Peaks were identified by comparison of their mass spectra to available standards or by spectral matches available in the NIST library. For example, the MS for peak 12 (C) is compared to the MS for authentic patchoulol (D). Other peak identifications: 1-.beta.-patchoulene; 2-.beta.-elemene; 3-.alpha.-cedrene (internal standard); 4-caryophyllene; 5-.alpha.-guaiene; 6-unknown; 7-.alpha.-patchoulene; 8-seychellene; 9-unknown, 10-.delta.-guaiene; 11-globulol; and 12-patchoulol.
 FIG. 1 is the result of a GC-MC analysis and illustrates that plants specifically transformed with genes encoding a specific, cytosol-targeted terpene (patchoulol) synthase of interest and a HMGR (A) had an altered terpene content if compared to the wild type (B) and accumulated patchoulol, besides other terpenes synthesised by the same patchoulol synthase.
 FIG. 4 is a quantitative analysis of sesquiterpene (patchoulol) content in leaves of plants transformed with PTS encoding, recombinant genes, wherein "PTS" alone refers to transformants harbouring a recombinant gene encoding a PTS, "FPS-PTS" refers to a gene encoding FPS fused to a gene encoding a PTS, and "FPS+PTS" refers to separated genes encoding a PTS a FPS. 14-8+PTS (8PTS) refers to plants over-expressing a HMGR gene according to the invention, while 14-2+PTS plants (2PTS, 2FPS-PTS, 2PTS+FPS) do not over-express HMGR. Seeds of the plant 8PTS 10 in FIG. 4 were deposited under ATCC PTA-6706.
 In FIG. 4 it can be seen that by transformation of plants with a TS (PTS) encoding gene alone, detectable expression of the protein is observed and was correlated with protein expression levels, but patchoulol accumulation was modest. By co-expressing the TS with a FPS, the accumulation of patchoulol was moderately increased. In contrast, expression of PTS in the 14-8 lines (HMGR over-expression) high patchoulol levels are observed which directly correlate with PTS protein expression levels (strain 10 in FIG. 3), compared with the same strain in FIG. 4. This results clearly demonstrating the strong contribution of HMGR to terpene accumulation.
Mendelian Crossing for Obtaining the Plants of the Invention
 Because of the difficulty to obtain transformed plants with the 14-8 line, classical mendelian crossing was used to generated plant lines overexpressing PTS alone (PTS), PTS with the FPP synthase (PTS+FPS) or as a fusion protein with the FPP synthase (FPS-PTS) together with HMGR. Transgenic plant lines engineered for expressing either PTS, PTS+FPS or FPS-PTS were initially germinated in the presence of hygromycin (15 mg/L) and only antibiotic resistant plants (comprising the desired construct) were grown up (parent line P1). Parental line P2 is homozygous for a truncated HMGR gene (14-8) (Chappell et al., 1995) and was germinated and grown without selection. Reciprocal crosses (pollen exchange between the two parental lines) yielded F1 progeny seeds that were germinated in the presence of kanamycin (50 mg/L) and hygromycin (15 mg/L) and the resulting resistant plants assessed for patchoulol accumulation as described above in Example 7. These double resistant plants contain the double insertion of a first construct encoding the truncated HMGR and a second construct encoding either PTS, FPS+PTS or FPS-PTS as illustrated in the FIG. 12 (part A).
 The resulting progeny plants, the F1 generation plants, were then evaluated for there accumulation of patchouol by GC-MS. In part B of FIG. 12, the patchoulol levels in parental lines (denoted in white) are shown relative to the corresponding progeny lines (reciprocal crosses--black and grey). The .DELTA.HMGR parental line (P2) did not accumulate any patchoulol. Table 1 bellow shows the numeric values of the same evaluations. The results demonstrate that engineering the patchoulol biosynthesis in the cytosol is significantly enhanced by simultaneously engineering of an unregulated form of HMGR. For all progeny plants resulting from the crosses an increase of 1.5 to 15 fold in patchoulol production was observed.
TABLE-US-00001 TABLE 1 Patchoulol Content in Different Transformed Plants and Progeny following Genetic Crossing Patchoulol (.mu.g/g fresh wt.) Fold Plant line T1 generation T1 .times. HMGR HMGR .times. T1 increase 2PTS - 5 1.7 .+-. 0.08 10.97 .+-. 2.96 9.02 .+-. 3.51 5.85 2PTS - 12 0.56 .+-. 0.02 8.59 .+-. 4.31 6.36 .+-. 2.08 13.13 2FPS - PTS-2 0.42 .+-. 0.06 1.27 .+-. 0.51 3.06 .+-. 1.31 5.13 2FPS - PTS-4 0.72 .+-. 0.03 2.08 .+-. 1.03 2.59 .+-. 1.29 3.25 2FPS + PTS-13 4.40 .+-. 0.87 8.31 .+-. 1.56 6.75 .+-. 1.42 1.71 2FPS + PTS-14 2.43 .+-. 0.68 6.31 .+-. 1.88 4.97 .+-. 0.55 2.27
RNA Extraction and Quantitative RT-PCR Analysis
 The total RNA of each line was isolated from 500 mg of young leaves with Trizol reagent according to the manufacturer (Invitrogen Life Technologies, Carlsbad, Calif.). First-strand cDNA was synthesized in 20 .mu.L reactions with 5 .mu.g of total RNA, 200 ng of oligodT12-16 primer and Reverse Transcriptase (Superscript II, Invitrogen Life Technologies) in reaction buffer and conditions as recommended by the manufacturer. One .mu.L of RNase H was subsequently added to the cDNA preparations and incubate at 37.degree. C. for 1 hour to remove complementary RNA.
 A quantitative RT-PCR method was used to determine mRNA levels in different transgenic lines. Optimal concentrations for linear PCR amplification were determined by varying the amount of added cDNA template and using number of PCR cycles (10, 15, 20, and 30). The primers PTS-8F and PTS-160R were used to amplify PTS gene, while FPP-1F and FPP-160R were used for the FPS gene. Another primer pair, RBCS-FW and RBCS-RV, was used to amplify the RUBisCO small subunit gene as an internal standard. Typical PCR conditions consisted of 1.times.Taq buffer (as supplied by the manufacturer), 1.5 mM MgCl.sub.2, 0.2 mM dNTP mixture, 0.5 .mu.M of each primers, 1.25 .mu.L cDNA, and 1 unit Taq DNA polymerase in a total of 25 .mu.L mixture. PCR amplifications was carried out for 20 temperature cycles, each consisting of denaturation at 94.degree. C. for 30 sec, annealing at 60.degree. C. for 30 sec, and extension at 72.degree. C. for 60 sec. PCR products were separated by agarose gel electrophoresis, stained with ethidium bromide, and photographed.
 The results of the PTS and FPS mRNA analysis is shown in FIG. 2. The figure shows RT-PCR products derived from mRNA isolated from plants transformed with constructs containing a patchoulol synthase (PTS) gene, or a construct containing a patchoulol synthase and a FPS genes (PTS+FPS), or a construct encoding for a fusion protein of FPS and PTS (FPS-PTS). RBCS is the RT-PCR product derived from the Rubisco small subunit mRNA, present in the wild-type (WT) and transgenic plants, and serves as an internal standard.
 It can be seen that wild-type (WT) plants did not express PTS or FPS. Most of the lines harboring the PTS, PTS+FPS and PTS-FPS contructs expressed readily detectable levels of the PTS mRNA, but patchoulol accumulation was relatively poorly correlated with the PTS mRNA expression levels.
Western Blotting Analysis
 A mixture of 4 to 5 synthesized peptides was used as antigens to prepare antibodies of PTS and FPS. The antigenic peptides were predicted by a free software (http://bio.dfci.harvard.edu/Tools/antigenic.html) and selected by direct 3Dstructural analysis (PDB: 1FPS) for FPS or homology model comparison with an available structure EAS (PDB: 5EAS) for PTS. We designed 5 antigenic peptides (PTS46: EELKVEL; PTS108: HATALSFRLLRQHGYRVSCE; PTS353: DEELIKLGAPYRA; PTS462: HVRTAVECYME; PTS475: KVGKQEVVSE) for PTS, and 4 antigenic peptides (FPP41: EFVGFFPQIVR; FPP59: GHPEVGDAVARLKEVLQY; FPP218: YKAIVKYKTAF-YSFYLPVAA; FPP320: PEKVAKVKELYEA) for FPS. All the peptides were synthesized in a 10 mg scale at immunological grade by Sigma-Genosys (The Woodland, Tex.). Each of the peptide mixtures were then conjugated to KLH (Keyhole Limpet Hemocyanin) carrier protein and injected into rabbits by Strategic Biosolutions (Windham, Me.). Polyclonal antibodies for PTS and FPS was further purified by preparative antigenic affinity column prepared with CNBR-activated sepharose 4B resin coupled with purified PTS or FPS protein according to the manufacturer's instruction (Amersham Biosciences, Buckinghamshire, England).
 To measure PTS and FPS protein levels in transgenic plant material, 100 mg of young leave material was ground in liquid nitrogen, then extracted with 800 .mu.L of 80 mM potassium phosphate (pH 7.0), 10% glycerol, 10 mM sodium metabisulfide, 15 mM MgCl.sub.2, 10 mM sodium ascorbate, 1% polyvinylpyrrolidone, and 14 mM .beta.-mercaptoethanol. The crude protein extracts were centrifuged at 4.degree. C. for 20 min at full speed in a table top microfuge, and the resulting supernatant used as the protein source. Samples containing 40 .mu.g of supernatant protein was electrophoresized in a 15% SDS-PAGE gel and blotted into a nitrocellulose membrane (BIO-RAD, Hercules, Calif.). Membranes were blocked with standard Tween 80/Tris-buffered saline (TTBS) blocking solution containing 5% dried milk before adding the purified PTS or FPS antibody. Membranes were then incubated for 3-7 hrs at room temperature with shaking, washed three times with TTBS, and then incubated with goat peroxidase labeled anti-rabbit IgG (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) in TTBS blocking solution for another 3 hours at room temperature. Chemiluminescent detection of the secondary antibody was performed with an ECL reagent kit according to the manufacturer's instructions (Amersham Biosciences, Buckinghamshire, England).
 Expression levels of the patchoulol synthase (PTS) and farnesyl diphosphate synthase (FPS) proteins in transgenic plants are shown in FIG. 3. The numbers above lanes in FIG. 3 represent independent transgenic plant lines engineered to contain a patchoulol synthase (PTS) gene, or a construct containing a patchoulol synthase and a FPS genes (PTS+FPS), or a construct encoding for a fusion protein of FPS and PTS (FPS-PTS). Results are shown for transgenic plants obtained by transformation with terpene synthase gene (patchoulol synthase) alone (2PTS) or with gene encoding a fusion protein (2PTS-FPS) and for plants obtained by transformation with a terpene synthase gene and further comprising a transgenic HMGR gene (8PTS) or further comprising a transgenic FPP synthase (2PTS+FPS). The positive control used are PTS and FPS proteins (respectively lanes PTS and FPS) purified from bacteria transformed to over-express these proteins. Lane WT1, extracts from leaves of a wild-type plant. Lane WT1, extract from leaves of plants only expressing the HMGR gene. Panel A shows membranes probed with the PTS antibodies and panel B shows a membrane probed with the FPS antibodies.
 It can be seen in FIG. 3 that no protein was immunologically detected in the wild type plants. For most of the transgenic lines analysed, PTS and/or FPS proteins could be detected in the leaf extracts and the expression level of the recombinant proteins in the leaves was correlated with the levels of terpene (patchoulol) accumulation.
[1-.sup.13C]-Glucose Labelling for Showing Pathway Used for Terpene Synthesis in Plants of the Present Invention
 To determine the biosynthetic origin of the carbon in the patchoulol accumulated, labbeling experiment was conducted and plants of the present invention were compared to plant engineered for plastidic production of patchoulol (PCT/IB2006/051198). Seeds of 8PTS10 (transgenic plant lines expressing PTS in the cytosol) and 2tpPTS+tpFPS12 (plastidic) were germinated on solid MS medium with the addition of hygromycin (15 mg/l).
 For GC-MS analysis, thirty 4-week-old seedlings were subsequently transferred to 25 ml flasks containing 5 ml of liquid MS medium without sucrose and incubated with gentle shaking (125 rpm) in the dark. One day later, 100 mg of [1-.sup.13C]-glucose (Sigma) was added into media and plant material collected at daily intervals. For GC analysis, 100 mg samples were extracted as described in Example 7.
 For NMR analysis, 1000 seedlings of above two transgenic lines were used, with 100 seedling grown in a 250 ml flask containing 50 ml of liquid MS medium with the addition of 1 g [1-.sup.13C]-glucose. All labeled seedlings were collected after one week and extracted as above. Concentrated extracts (3 ml) were then purified by preparative TLC separations using silica TLC plates and hexane:ethylacetate (9:1) as the developing solvent.
 250 .mu.g of purified .sup.13C-labeled patchoulol from line 2tpPTS+tpFPS12 and 500 .mu.g from 8PTS10 were subsequently analyzed by .sup.13C-NMR (750 mHz, CDCl.sub.3 by Bob Coates in the Chemistry Department, University of Illinois, Champaign, Ill.). Carbon positions and enrichments were assigned relative to un-labeled patchoulol purified from control plants.
 FIG. 13A shows the predicted .sup.13C labelling patterns in patchoulol synthesised from IPP emerging from the MVA and the MEP pathway, respectively, in transgenic seedlings fed on [1-.sup.13C]-glucose. Patchoulol synthesised from IPP of the MVA pathway is predicted to have 9 .sup.13C-carbons at positions 1, 3, 5, 7, 9, 12, 13 14 and 15, whereas its counterpart from the MEP pathway is expected to have only 6 .sup.13C-carbons, namely art positions 2, 6, 8, 12, 13 and 15.
 Results of GC-MS analysis are shown in FIG. 13B, in which Figure b shows MS parent ions for patchoulol synthesised by plants fed .sup.12C-glucose (control) and Figures c and d plants fed on .sup.13C-glucose producing patchoulol by the (cytosolic) MVA and (plastidic) MEP pathway, respectively. It can be seen that patcholoul emerging from plants fed on .sup.13C have heavier ions, with the effect being less pronounced with the plastidic patchoulol: the mass of the major parent ion is shift from 222 to 225, and an M+8 mass parent ion can be observed when the cytosolic pathway is engineered; and the mass of the major parent ion is shifted to 224 and an M+6 mass parent ion can be observed when the chloroplast pathway is engineered. These observation are consistent with the labelling prediction. Results of NRM-analysis are shown in Table 2 below.
TABLE-US-00002 TABLE 2 .sup.13C enrichment into pachoulol synthesized by the cytosoloic MVA and plastidic MEP pathways from 1-C.sup.13-glucose % .sup.13C 2tpPTS + Carbon atom Dc (ppm) 8PTS-10 tpFPS-12 1 74.9 13.0 0.0 2 33.1 3.0 13.8 3 28.9 21.8 4.2 4 28.1 2.9 2.7 5 43.8 19.1 2.4 6 24.5 22.2* 18.4 7 39.4 19.3 2.7 8 24.9 2.9 17.3 9 29.1 17.1 3.6 10 37.8 1.6 2.0 11 40.3 1.4 4.0 12 18.8 22.9 19.1 13 20.9 20.2 17.9 14 27.3 22.0 6.1 15 24.7 15.8 13.8 *signal due to contaminate
 In accordance with predicted labelling patterns shown in FIG. 13, Table 2 shows that in patchoulol from plants having PTS expressed in the cytosol, carbon atoms 1, 3, 5, 7, 9, 12, 13, 14 and 15 are enriched with 13C. The labelling thus shows that the sesquiterpene is actually synthesised from IPP resulting from the MVA-pathway and that there is now contribution of the plastidic pathway.
Engineering of the Cytosolic Monoterpene Biosynthesis in Plants
 The expression vectors shown in FIG. 7 were generated by substitution cloning of a citrus limonene synthase gene (LIS) (GenBank accession AF514287) for the PTS gene, and a geranyl diphosphate synthase gene (GPS) from Arabidopsis thaliana (GenBank accession ATH17376) for the FPS gene in the original PTS and FPS expression vectors as illustrated in FIG. 11. The LIS and GPS genes were obtained by a reverse transcription-PCR amplification of the respective genes from RNA isolated from lemon fruits or Arabidopsis plants, respectively. The RNA were extracted using the RNA-Trizol (invitrogen) reagent according to the manufacturer protocol and converted to first strand cDNA using a reverse transcriptase and an oligodT primer. The PCR amplifications were performed using the primers combination AtGPS-SpeF and AtGPS-KpnR for the amplification of GPS and the primers combination LIS-AscF and LIS-XhoR for the amplification of LIS (30, 31). These primers were designed to remove the nucleotidic sequence encoding plastid targeting signal, to introduce a start codon and to introduce restriction enzyme recognition sites. The PCR products containing the LIS gene (32) was digested with the XhoI and AscI restriction enzymes and ligated in the corresponding site of the original PTS expression vector (33) digested with the same enzymes (34). The resulting vector (35) was used for LIS expression in plants. For the construction of the LIS and GPS expression vector, the PCR product containing the GPS gene (36), obtained as described above, was digested with the KpnI and SpeI restriction enzymes and ligated in the PTS+FPS expression vector (37) digested with the same enzymes (38) to obtain the vector 39 (FIG. 11). The PCR product containing the LIS gene and digested with the XhoI and AscI restriction enzymes (32) was obtained as described above and was ligated in the vector 40 first digested with the same enzymes (42). The resulting vector (41) was used to express LIS and GPS in plants.
 Plants were transformed according to Example 6 and evaluated for limonene accumulation according to Example 7. In FIG. 15 it can be seen that limonene was accumulated in the plant engineered for the cytosolic pathway and that for some plants coexpression of GPS with LIS increased the accumulation of limonene.
 Ausubel F M, Brent R, Kingston R E, Moore D D, Seidman J G, Smith J A, Struhl K (1987) Current Protocols in Molecular Biology.  Benfey P N, Chua N H (1990) The Cauliflower Mosaic Virus-35S Promoter--Combinatorial Regulation Of Transcription In Plants. Science 250: 959-966  Chappell J, Wolf F, Proulx J, Cuellar R, Saunders C (1995) Is The Reaction Catalyzed By 3-Hydroxy-3-Methylglutaryl Coenzyme-A Reductase A Rate-Limiting Step For Isoprenoid Biosynthesis In Plants. Plant Physiology 109: 1337-1343  Chin D J, Gil G, Russell D W, Liscum L, Luskey K L, Basu S K, Okayama H, Berg P, Goldstein J L, Brown M S (1984) Nucleotide-Sequence Of 3-Hydroxy-3-Methyl-Glutaryl Coenzyme-A Reductase, A Glycoprotein Of Endoplasmic-Reticulum. Nature 308: 613-617  Frey P M, Scharer-Hernandez N G, Futterer J, Potrykus I, Puonti-Kaerlas J (2001) Simultaneous analysis of the bidirectional African cassaya mosaic virus promoter activity using two different luciferase genes. Virus Genes 22: 231-242  Hajdukiewicz P, Svab Z, Maliga P (1994) The Small, Versatile Ppzp Family Of Agrobacterium Binary Vectors For Plant Transformation. Plant Molecular Biology 25: 989-994  Hartley J L, Temple G F, Brasch M A (2000) DNA cloning using in vitro site-specific recombination. Genome Research 10: 1788-1795  Horsch R B, Fry J E, Hoffmann N L, Eichholtz D, Rogers S G, Fraley R T (1985) A Simple And General-Method For Transferring Genes Into Plants. Science 227: 1229-1231  Lucker et al (2001) Expression of Clarkia S-linalool synthase in transgenic petunia plants results in the accumulation of S-linalyl-beta-D-glucopyranoside; Plant J. (4):315-24  Mau C J, West C A (1994) Cloning of casbene synthase cDNA: evidence for conserved structural features among terpenoid cyclases in plants Proc Natl Acad Sci USA; 91(18):8497-501.  Mersereau M, Pazour G J, Das A (1990) Efficient Transformation Of Agrobacterium-Tumefaciens By Electroporation. Gene 90: 149-151  Murashige T, Skoog F (1962) A Revised Medium For Rapid Growth And Bio Assays With Tobacco Tissue Cultures. Physiologia Plantarum 15: 473-&  Ohara et al (2003) Limonene production in tobacco with Perilla limonene synthase cDNA. J. Exp. Bot.  Peters et al (2000) Biochemistry; 39(50):15592-602  Sambrook J, Fritsch E F, Maniatis T (1989) Molecular Cloning--a laboratory manual (2nd Edition). Cold Spring Harbor Press, Cold Spring Harbor, N.Y.  Schardl C L, Byrd A D, Benzion G, Altschuler M A, Hildebrand D F, Hunt A G (1987) Design And Construction Of A Versatile System For The Expression Of Foreign Genes In Plants. Gene 61: 1-11  Shirai, K., Masuda, K. and Oosawa, K. 2002. Cloning and Sequencing of Ent-kKaurene Synthase cDNA from Cucumber. Acta Hort. (ISHS) 588:317-320  Takahashi S, Zhao Y, O'Maille P E, Greenhagen B T, Noel J P, Coates R M, Chappell J (2005) Kinetic and molecular analysis of 5-epiaristolochene-1,3-dihydroxylase, a cytochrome P450 enzyme catalyzing successvie hydroxylations of sesquiterpenes. Journal of Biological Chemistry 280: 3686-3696  Tarshis L C, Yan M J, Poulter C D, Sacchettini J C (1994) Crystal-Structure Of Recombinant Farnesyl Diphosphate Synthase At 2.6-Angstrom Resolution. Biochemistry 33: 10871-10877
5711659DNAProgostemon cablin 1atggagttgt atgcccaaag tgttggagtg ggtgctgctt ctcgtcctct tgcgaatttt 60catccatgtg tgtggggaga caaattcatt gtctacaacc cacaatcatg ccaggctgga 120gagagagaag aggctgagga gctgaaagtg gagctgaaaa gagagctgaa ggaagcatca 180gacaactaca tgcggcaact gaaaatggtg gatgcaatac aacgattagg cattgactat 240ctttttgtgg aagatgttga tgaagctttg aagaatctgt ttgaaatgtt tgatgctttc 300tgcaagaata atcatgacat gcacgccact gctctcagct ttcgccttct cagacaacat 360ggatacagag tttcatgtga agtttttgaa aagtttaagg atggcaaaga tggatttaag 420gttccaaatg aggatggagc ggttgcagtc cttgaattct tcgaagccac gcatctcaga 480gtccatggag aagacgtcct tgataatgct tttgacttca ctaggaacta cttggaatca 540gtctatgcaa ctttgaacga tccaaccgcg aaacaagtcc acaacgcatt gaatgagttc 600tcttttcgaa gaggattgcc acgcgtggaa gcaaggaagt acatatcaat ctacgagcaa 660tacgcatctc atcacaaagg cttgctcaaa cttgctaagc tggatttcaa cttggtacaa 720gctttgcaca gaagggagct gagtgaagat tctaggtggt ggaagacttt acaagtgccc 780acaaagctat cattcgttag agatcgattg gtggagtcct acttctgggc ttcgggatct 840tatttcgaac cgaattattc ggtagctagg atgattttag caaaagggct ggctgtatta 900tctcttatgg atgatgtgta tgatgcatat ggtacttttg aggaattaca aatgttcaca 960gatgcaatcg aaaggtggga tgcttcatgt ttagataaac ttccagatta catgaaaata 1020gtatacaagg cccttttgga tgtgtttgag gaagttgacg aggagttgat caagctaggc 1080gcaccatatc gagcctacta tggaaaagaa gccatgaaat acgccgcgag agcttacatg 1140gaagaggccc aatggaggga gcaaaagcac aaacccacaa ccaaggagta tatgaagctg 1200gcaaccaaga catgtggcta cataactcta ataatattat catgtcttgg agtggaagag 1260ggcattgtga ccaaagaagc cttcgattgg gtgttctccc gacctccttt catcgaggct 1320acattaatca ttgccaggct cgtcaatgat attacaggac acgagtttga gaaaaaacga 1380gagcacgttc gcactgcagt agaatgctac atggaagagc acaaagtggg gaagcaagag 1440gtggtgtctg aattctacaa ccaaatggag tcagcatgga aggacattaa tgaggggttc 1500ctcagaccag ttgaatttcc aatccctcta ctttatctta ttctcaattc agtccgaaca 1560cttgaggtta tttacaaaga gggcgattcg tatacacacg tgggtcctgc aatgcaaaac 1620atcatcaagc agttgtacct tcaccctgtt ccatattaa 165921137DNAGallus gallus 2atgcagcccc atcatcatca taaagagggg cgtatgcata aatttactgg tgtcaatgcc 60aagtttcagc aacccgcgtt gaggaacctc agccccgtgg tggttgagag ggagagggag 120gagttcgtgg ggttcttccc gcagatcgtc cgcgatctga ccgaggacgg catcggacac 180ccggaggtgg gcgacgctgt ggcgcggctg aaggaggtgc tgcaatacaa cgctcccggt 240gggaaatgca accgtgggct gacggtggtg gctgcgtacc gggagctgtc ggggccgggg 300cagaaggatg ctgagagcct gcggtgcgcg ctggccgtgg gttggtgcat cgagttgttc 360caggccttct tcctggtggc tgatgatatc atggatcagt ccctcacgcg ccgggggcag 420ctgtgttggt ataagaagga gggggtcggt ttggatgcca tcaacgactc cttcctcctc 480gagtcctctg tgtacagagt gctgaagaag tactgcaggc agcggccgta ttacgtgcat 540ctgttggagc tcttcctgca gaccgcctac cagactgagc tcgggcagat gctggacctc 600atcacagctc ccgtctccaa agtggatttg agtcacttca gcgaggagag gtacaaagcc 660atcgttaagt acaagactgc cttctactcc ttctacctac ccgtggctgc tgccatgtat 720atggttggga tcgacagtaa ggaagaacac gagaatgcca aagccatcct gctggagatg 780ggggaatact tccagatcca ggatgattac ctggactgct ttggggaccc ggcgctcacg 840gggaaggtgg gcaccgacat ccaggacaat aaatgcagct ggctcgtggt gcagtgcctg 900cagcgcgtca cgccggagca gcggcagctc ctggaggaca actacggccg taaggagccc 960gagaaggtgg cgaaggtgaa ggagctgtat gaggccgtgg ggatgagggc tgcgttccag 1020cagtacgagg agagcagcta ccggcgcctg caggaactga tagagaagca ctcgaaccgc 1080ctcccgaagg agatcttcct cggcctggca cagaagatct acaaacgcca gaaatga 113732802DNAArtificialDNA encodes fusion protein FPS-PTS 3atgcagcccc atcatcatca taaagagggg cgtatgcata aatttactgg tgtcaatgcc 60aagtttcagc aacccgcgtt gaggaacctc agccccgtgg tggttgagag ggagagggag 120gagttcgtgg ggttcttccc gcagatcgtc cgcgatctga ccgaggacgg catcggacac 180ccggaggtgg gcgacgctgt ggcgcggctg aaggaggtgc tgcaatacaa cgctcccggt 240gggaaatgca accgtgggct gacggtggtg gctgcgtacc gggagctgtc ggggccgggg 300cagaaggatg ctgagagcct gcggtgcgcg ctggccgtgg gttggtgcat cgagttgttc 360caggccttct tcctggtggc tgatgatatc atggatcagt ccctcacgcg ccgggggcag 420ctgtgttggt ataagaagga gggggtcggt ttggatgcca tcaacgactc cttcctcctc 480gagtcctctg tgtacagagt gctgaagaag tactgcaggc agcggccgta ttacgtgcat 540ctgttggagc tcttcctgca gaccgcctac cagactgagc tcgggcagat gctggacctc 600atcacagctc ccgtctccaa agtggatttg agtcacttca gcgaggagag gtacaaagcc 660atcgttaagt acaagactgc cttctactcc ttctacctac ccgtggctgc tgccatgtat 720atggttggga tcgacagtaa ggaagaacac gagaatgcca aagccatcct gctggagatg 780ggggaatact tccagatcca ggatgattac ctggactgct ttggggaccc ggcgctcacg 840gggaaggtgg gcaccgacat ccaggacaat aaatgcagct ggctcgtggt gcagtgcctg 900cagcgcgtca cgccggagca gcggcagctc ctggaggaca actacggccg taaggagccc 960gagaaggtgg cgaaggtgaa ggagctgtat gaggccgtgg ggatgagggc tgcgttccag 1020cagtacgagg agagcagcta ccggcgcctg caggaactga tagagaagca ctcgaaccgc 1080ctcccgaagg agatcttcct cggcctggca cagaagatct acaaacgcca gaaaggcgcg 1140ccgatggagt tgtatgccca aagtgttgga gtgggtgctg cttctcgtcc tcttgcgaat 1200tttcatccat gtgtgtgggg agacaaattc attgtctaca acccacaatc atgccaggct 1260ggagagagag aagaggctga ggagctgaaa gtggagctga aaagagagct gaaggaagca 1320tcagacaact acatgcggca actgaaaatg gtggatgcaa tacaacgatt aggcattgac 1380tatctttttg tggaagatgt tgatgaagct ttgaagaatc tgtttgaaat gtttgatgct 1440ttctgcaaga ataatcatga catgcacgcc actgctctca gctttcgcct tctcagacaa 1500catggataca gagtttcatg tgaagttttt gaaaagttta aggatggcaa agatggattt 1560aaggttccaa atgaggatgg agcggttgca gtccttgaat tcttcgaagc cacgcatctc 1620agagtccatg gagaagacgt ccttgataat gcttttgact tcactaggaa ctacttggaa 1680tcagtctatg caactttgaa cgatccaacc gcgaaacaag tccacaacgc attgaatgag 1740ttctcttttc gaagaggatt gccacgcgtg gaagcaagga agtacatatc aatctacgag 1800caatacgcat ctcatcacaa aggcttgctc aaacttgcta agctggattt caacttggta 1860caagctttgc acagaaggga gctgagtgaa gattctaggt ggtggaagac tttacaagtg 1920cccacaaagc tatcattcgt tagagatcga ttggtggagt cctacttctg ggcttcggga 1980tcttatttcg aaccgaatta ttcggtagct aggatgattt tagcaaaagg gctggctgta 2040ttatctctta tggatgatgt gtatgatgca tatggtactt ttgaggaatt acaaatgttc 2100acagatgcaa tcgaaaggtg ggatgcttca tgtttagata aacttccaga ttacatgaaa 2160atagtataca aggccctttt ggatgtgttt gaggaagttg acgaggagtt gatcaagcta 2220ggcgcaccat atcgagccta ctatggaaaa gaagccatga aatacgccgc gagagcttac 2280atggaagagg cccaatggag ggagcaaaag cacaaaccca caaccaagga gtatatgaag 2340ctggcaacca agacatgtgg ctacataact ctaataatat tatcatgtct tggagtggaa 2400gagggcattg tgaccaaaga agccttcgat tgggtgttct cccgacctcc tttcatcgag 2460gctacattaa tcattgccag gctcgtcaat gatattacag gacacgagtt tgagaaaaaa 2520cgagagcacg ttcgcactgc agtagaatgc tacatggaag agcacaaagt ggggaagcaa 2580gaggtggtgt ctgaattcta caaccaaatg gagtcagcat ggaaggacat taatgagggg 2640ttcctcagac cagttgaatt tccaatccct ctactttatc ttattctcaa ttcagtccga 2700acacttgagg ttatttacaa agagggcgat tcgtatacac acgtgggtcc tgcaatgcaa 2760aacatcatca agcagttgta ccttcaccct gttccatatt aa 280241668DNACitrus limon 4atgaggagat cagcaaacta ccaaccttca atttgggacc acgatttttt gcagtcattg 60aatagcaact atacggatga agcatacaaa agacgagcag aagagctgag gggaaaagtg 120aagatagcga ttaaggatgt aatcgagcct ctggatcagt tggagctgat tgataacttg 180caaagacttg gattggctca tcgttttgag actgagatta ggaacatatt gaataatatc 240tacaacaata ataaagatta taattggaga aaagaaaatc tgtatgcaac ctcccttgaa 300ttcagactac ttagacaaca tggctatcct gtttctcaag aggttttcaa tggttttaaa 360gacgaccagg gaggcttcat ttgtgatgat ttcaagggaa tactgagctt gcatgaagct 420tcgtattaca gcttagaagg agaaagcatc atggaggagg cctggcaatt tactagtaaa 480catcttaaag aagtgatgat cagcaagaac atggaagagg atgtatttgt agcagaacaa 540gcgaagcgtg cactggagct ccctctgcat tggaaagtgc caatgttaga ggcaaggtgg 600ttcatacaca tttatgagag aagagaggac aagaaccacc ttttacttga gctcgctaag 660atggagttta acactttgca ggcaatttac caggaagaac taaaagaaat ttcagggtgg 720tggaaggata caggtcttgg agagaaattg agctttgcga ggaacaggtt ggtagcgtcc 780ttcttatgga gcatggggat cgcgtttgag cctcaattcg cctactgcag gagagtgctc 840acaatctcga tagccctaat tacagtgatt gatgacattt atgatgtcta tggaacattg 900gatgaacttg agatattcac tgatgctgtt gagaggtggg acatcaatta tgctttgaag 960caccttccgg gctatatgaa aatgtgtttt cttgcgcttt acaactttgt taatgaattt 1020gcttattacg ttctcaaaca acaggatttt gatttgcttc tgagcataaa aaatgcatgg 1080cttggcttaa tacaagccta cttggtggag gcgaaatggt accatagcaa gtacacaccg 1140aaactggaag aatacttgga aaatggattg gtatcaataa cgggcccttt aattataacg 1200atttcatatc tttctggtac aaatccaatc attaagaagg aactggaatt tctagaaagt 1260aatccagata tagttcactg gtcatccaag attttccgtc tgcaagatga tttgggaact 1320tcatcggacg agatacagag aggggatgtt ccgaaatcaa tccagtgtta catgcatgaa 1380actggtgcct cagaggaagt tgctcgtcaa cacatcaagg atatgatgag acagatgtgg 1440aagaaggtga atgcatacac agccgataaa gactctccct tgactggaac aactactgag 1500ttcctcttga atcttgtgag aatgtcccat tttatgtatc tacatggaga tgggcatggt 1560gttcaaaacc aagagactat cgatgtcggt tttacattgc tttttcagcc cattcccttg 1620gaggacaaac acatggcttt cacagcatct cctggcacca aaggctga 166851035DNAArabidopsis thaliana 5atggaggagc ttgacccatt ttcgcttgtt gccgatgagc tgtcacttct tagtaataag 60ttgagagaga tggtacttgc cgaggttcca aagcttgcct ctgctgctga gtacttcttc 120aaaaggggtg tgcaaggaaa acagtttcgt tcaactattt tgctgctgat ggcgacagct 180ctggatgtac gagttccaga agcattgatt ggggaatcaa cagatatagt cacatcagaa 240ttacgcgtaa ggcaacgggg tattgctgaa atcactgaaa tgatacacgt cgcaagtcta 300ctgcacgatg atgtcttgga tgatgccgat acaaggcgtg gtgttggttc cttaaatgtt 360gtaatgggta acaagatgtc ggtattagca ggagacttct tgctctcccg ggcttgtggg 420gctctcgctg ctttaaagaa cacagaggtt gtagcattac ttgcaactgc tgtagaacat 480cttgttaccg gtgaaaccat ggagataact agttcaaccg agcagcgtta tagtatggac 540tactacatgc agaagacata ttataagaca gcatcgctaa tctctaacag ctgcaaagct 600gttgccgttc tcactggaca aacagcagaa gttgccgtgt tagcttttga gtatgggagg 660aatctgggtt tagcattcca attaatagac gacattcttg atttcacggg cacatctgcc 720tctctcggaa agggatcgtt gtcagatatt cgccatggag tcataacagc cccaatcctc 780tttgccatgg aagagtttcc tcaactacgc gaagttgttg atcaagttga aaaagatcct 840aggaatgttg acattgcttt agagtatctt gggaagagca agggaataca gagggcaaga 900gaattagcca tggaacatgc gaatctagca gcagctgcaa tcgggtctct acctgaaaca 960gacaatgaag atgtcaaaag atcgaggcgg gcacttattg acttgaccca tagagtcatc 1020accagaaaca agtga 1035627DNAArtificialPrimer (Attp1-SstI-FW) 6agtcacgagc tcgtaaaacg acggcca 27723DNAArtificialPrimer (Attp2-SphI-RV) 7gcatgccagg aaacagctat gac 23826DNAArtificialPrimer (HPT-NotI-FD) 8gcggccgcat gaaaaagcct gaactc 26925DNAArtificialPrimer (HPT-Xba1-RV) 9tctagataat tcgggggatc tggat 251026DNAArtificialPrimer (TB-SphI-FD) 10gtggttggca tgcacataca aatgga 261126DNAArtificialPrimer (TB-NotI-RV) 11gcggccgcgc gaaacgatcc agatcc 261228DNAArtificialPrimer (HPT-SphI-RV) 12ggggcatgct aattcggggg atctggat 281356DNAArtificialPrimer (CSMV-ATTB1-SGFI-FD) 13ggggacaagt ttgtacaaaa aagcaggctg cgatcgccct atgttcaaaa atgaag 561431DNAArtificialPrimer (CSMV-ECORI-RV) 14tacgaattca caaatttctc tgaagttgta t 311531DNAArtificialPrimer (Tnos-XhoI-FW) 15cggatgctcg aggatcgttc aaacatttgg c 311649DNAArtificialPrimer (Tnos-attB2-RV) 16ggggaccact ttgtacaaga aagctgggtg atctagtaac atagatgac 491735DNAArtificialPrimer (His-EcoF) 17aattcggcgc gccatgcatc atcatcatca tcacg 351835DNAArtificialPrimer (His-EcoR) 18aattcgtgat gatgatgatg atgcatggcg cgccg 351944DNAArtificialPrimer (mHisPTS-F) 19cttcagagaa atttgtgaat tatacatcat catcatcatc acgg 442044DNAArtificialPrimer (mHisPTS-R) 20ccgtgatgat gatgatgatg tataattcac aaatttctct gaag 442131DNAArtificialPrimer (TP-ASCF) 21ttggcgcgcc tatggcttcc tctatgctct c 312231DNAArtificialPrimer (TP-ASCR) 22ttggcgcgcc cttcatgcag ctagatcttc c 312331DNAArtificialPrimer (PCaMV-XbaI-FW) 23tcagtttcta gacatggagt caaagattca a 312427DNAArtificialPrimer (PCaMV-SpeI-RV) 24accatgacta gtcccccgtg ttctctc 272528DNAArtificialPrimer (FPS-SpeI-FW) 25actagtatgc aattcttcag cttggttt 282633DNAArtificialPrimer (FPS-KpnI-RV) 26cggggtacct tactcccgag aaggttgata agg 332728DNAArtificialPrimer (Tnos-KpnI-FW) 27cggggtaccg atcgttcaaa catttggc 282821DNAArtificialPrimer (Tnos-attB2-RV3) 28gagctcgggg accactttgt a 212956DNAArtificialPrimer (CsMV-attB1-SgfI-FD) 29ggggacaagt ttgtacaaaa aagcaggctg cgatcgccct atgttcaaaa atgaag 563028DNAArtificialPrimer (TNOS-XbaI-RV) 30gctctagaga tctagtaaca tagatgac 283130DNAArtificialPrimer (TP-SpeFW) 31ggggactagt atggcttcct ctatgctctc 303231DNAArtificialPrimer (TP-SpeRV) 32ggggactagt cttcatgcag ctagatcttc c 313334DNAArtificialPrimer (PTS-AscF) 33ggggagctcg gcgcgccgat ggagttgtat gccc 343431DNAArtificialPrimer (PTS-XhoR) 34ggggctcgag ttaatatgga acagggtgaa g 313535DNAArtificialPrimer (FPP-SpeFW) 35ggggactagt atgcagcccc atcatcatca taaag 353631DNAArtificialPrimer (FPP-KpnRV) 36cggggtacct catttctggc gtttgtagat c 313730DNAArtificialPrimer (FPS-AscF) 37ttggcgcgcc tatgcagccc catcatcatc 303830DNAArtificialPrimer (FPS-AscR) 38ttggcgcgcc ttttctggcg tttgtagatc 303924DNAArtificialPrimer (PTS-8F) 39gagtgggtgc tgcttctcgt cctc 244024DNAArtificialPrimer (PTS-160R) 40ctccatggac tctgagatgc gtgg 244126DNAArtificialPrimer (FPP-1F) 41gcagccccat catcatcata aagagg 264223DNAArtificialPrimer (FPP-160R) 42gaggactcga ggaggaagga gtc 234321DNAArtificialPrimer (RBCS-FW) 43atgcaggtgt ggccaccaat t 214421DNAArtificialPrimer (RBCS-RV) 44ttagtagcct tctggcttgt a 214533DNAArtificialPrimer (AtGPS-SpeF) 45ggactagtat ggaggagctt gacccatttt cgc 334631DNAArtificialPrimer (AtGPS-KpnR) 46ggggtacctc acttgtttct ggtgatgact c 314737DNAArtificialPrimer (LIS-AscF) 47gggggcgcgc cgatgaggag atcagcaaac taccaac 374834DNAArtificialPrimer (LIS-XhoR) 48ggggctcgag tcagcctttg gtgccaggag atgc 34497PRTArtificialAntigenic peptide (PTS46) 49Glu Glu Leu Lys Val Glu Leu1 55020PRTArtificialAntigenic peptide (PTS108) 50His Ala Thr Ala Leu Ser Phe Arg Leu Leu Arg Gln His Gly Tyr Arg1 5 10 15Val Ser Cys Glu205113PRTArtificialAntigenic peptide (PTS353) 51Asp Glu Glu Leu Ile Lys Leu Gly Ala Pro Tyr Arg Ala1 5 105211PRTArtificialAntigenic peptide (PTS462) 52His Val Arg Thr Ala Val Glu Cys Tyr Met Glu1 5 105310PRTArtificialAntigenic peptide (PTS475) 53Lys Val Gly Lys Gln Glu Val Val Ser Glu1 5 105411PRTArtificialAntigenic peptide (FPP41) 54Glu Phe Val Gly Phe Phe Pro Gln Ile Val Arg1 5 105518PRTArtificialAntigenic peptide (FPP59) 55Gly His Pro Glu Val Gly Asp Ala Val Ala Arg Leu Lys Glu Val Leu1 5 10 15Gln Tyr5620PRTArtificialAntigenic peptide (FPP218) 56Tyr Lys Ala Ile Val Lys Tyr Lys Thr Ala Phe Tyr Ser Phe Tyr Leu1 5 10 15Pro Val Ala Ala205713PRTArtificialAntigenic peptide (FPP320) 57Pro Glu Lys Val Ala Lys Val Lys Glu Leu Tyr Glu Ala1 5 10
The PDF for this patent has not yet been downloaded.
If you would like to download it please click the 'Retrieve PDF' button at the top of your screen